Response Genetics gains Medicare-approved cancer Dx in asset sale

Response Genetics ($RGDX) snatched up the remnants of a defunct rival and gained an FDA-cleared, revenue-generating test in the process.

The Los Angeles company said it now owns "the key assets" of Pathwork Diagnostics, acquired with $200,000 in cash, plus 500,000 shares of Response Genetics common stock. The big prize: a diagnostic test cleared in June 2010 to spot metastatic tumors and cancers whose origin is hard to determine.

Response Genetics chairman and CEO Thomas Bologna said in a statement that the deal reflects the company's ongoing goal to grow "both organically and through a series of acquisitions."

In particular, acquiring the assets of a company that went out of business gives Response a cost-effective way to grow and generate revenue. Response develops and sells molecular diagnostic tests for cancer, so the deal represents a good fit on that level alone. But the company now has an instant, FDA-cleared test that has already obtained Medicare reimbursement, something increasingly hard to come by these days for diagnostics makers.

Response bills the acquisition as a big deal, in part because use of the Pathwork test had been growing, and it reached "mid-seven-figure" sales in 2012. And so the test could be a real revenue generator. Response Genetics has focused on boosting revenue this year, with $5.3 million booked in its fiscal 2013 second quarter, though losses continues as the company ramps up its sales force and pursues wider marketing of its products.

The test uses a proprietary microarray platform and proprietary software to compare the expression of 2,000 genes in a patient's tumor with a panel of 15 known tumor types covering most cancers, the company explains.

And Response Genetics is drawing interest from Big Pharma. Last year, GlaxoSmithKline ($GSK) acquired 5 million newly issued shares in the company. The deal built on an ongoing relationship in which Response conducts companion diagnostic tests for GSK's immunotherapy and cancer pipeline drug candidates.

- read the release
- here's Response's recent Q2 financials

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.